Rozemeijer R, et al. - Researchers compared polymer-free amphilimus-eluting stents (PF-AES) to latest-generation permanent polymer zotarolimus-eluting stents (PP-ZES) in terms of 1-year clinical outcomes in a real-world all-comers setting. Patients treated with either PF-AES or PP-ZES between 2014 and 2016 were included in a prospective registry. Participants were 734 consecutive patients with 1,269 drug-eluting stent (DES) implantations; 28% with diabetes, 24% with ST-segment elevation myocardial infarction, and 69% with complex lesions. For PF-AES and for PP-ZES, the rate of major adverse cardiac and cerebrovascular events (MACCE) was 11.5% and 13.6%, respectively. A trend toward a lower rate of MACCE and a favorable rate of target-lesion failure (TLF) was observed with PF-AES vs PP-ZES following propensity-score adjustment. Also, low rates of definite ST were reported. Overall, PF-AES offered low-rates of MACCE and TLF at 1 year and its implantation was found to be safe and effective in real-world patients.